

ANRS CO2 SEROCO/HEMOCO - Multicentric Cohort of HIV Positive Patients

Head :Meyer Laurence, U822

Last update : 01/01/2019 | Version : 2 | ID : 60080

General

Identification

Detailed name Multicentric Cohort of HIV Positive Patients

Sign or acronym ANRS CO2 SEROCO/HEMOCO

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL no. 87-108 (17/11/1987)

General Aspects

Medical area Infectious diseases

Health determinants Geography
Social and psychosocial factors

Keywords AIDS stage, morbidity, mortality, health events

Scientific investigator(s) (Contact)

Name of the director Meyer

Surname Laurence

Address 94276 LE KREMLIN BICÊTRE

Phone +33 (0)1 45 21 23 34

Email laurence.meyer@inserm.fr

Unit U822

Organization INSERM - Institut National de Santé et Recherche

Collaborations

Participation in projects, networks and consortia Yes

Details	Involved in cohort network: COHORTES AC7, HEPAVIH - international: COHERE, EUROPEAN COHORT OF INJECTION DRUG USERS (Mr. PRINS, NETHERLANDS), CASCADE Involved in a European project: Cascade, Cohere.
Funding	
Funding status	Public
Details	ANRS
Governance of the database	
Sponsor(s) or organisation(s) responsible	Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS)
Organisation status	Public
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Inclusion method: Prospective Inclusion cut-off date: 01/01/2001
Database objective	
Main objective	General objective: to investigate spontaneous HIV disease progression and the treatment response of haemophilic (HEMOCO) or non-haemophilic (SEROCCO) subjects. The prognostic role of markers, in particular CD4, HIV-RNA and HIV-DNA.
Inclusion criteria	SEROCCO: Seropositive HIV-1 patients (ELISA test confirmed by Western blot) with known date of contamination or whose HIV status is less than a year old (period between first positive sample date and the date the patient is enrolled in survey) and who do not have AIDS at baseline; attending

physicians from centres participating in the survey; who are 18 years old or over and have given their informed consent.

HEMOCO: HIV-seropositive haemophiliacs (ELISA test confirmed by Western blot); attending physicians from centres participating in the survey, who are 3 years old and over and have given their informed consent. Consent is signed by the parties with parental authority of dependent minors or by the legal guardians of minors under tutelage.

Population type

Age
Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)

Population covered
Sick population

Gender
Male
Woman

Geography area
Regional

French regions covered by the database
Île-de-France
Provence - Alpes - Côte d'Azur

Detail of the geography area
Paris regions and PACA (21 centres).

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)
01/1988

Date of last collection (YYYY or MM/YYYY)
01/2009

Size of the database

Size of the database (number of individuals)
[1000-10 000[individuals

Details of the number of individuals
- 1551 (SEROCO) - 197 (HEMOCO)

Data

Database activity
Data collection completed

Type of data collected
Clinical data

	Declarative data Biological data
Clinical data (detail)	Direct physical measures Medical registration
Details of collected clinical data	Clinical examination at baseline and every 6-month follow-up. Information collected during clinical examination: clinical, virological, immunological data, initiation and interruption of several antiretroviral drugs.
Declarative data (detail)	Paper self-questionnaire Face to face interview
Details of collected declarative data	Information collected by self-administered questionnaire: sexual behaviour. Interview questionnaire at baseline and every 6-month follow-up. Information collected during interview: behavioural practices.
Biological data (detail)	Type of samples taken: blood.
Presence of a biobank	Yes
Contents of biobank	Serum Fluids (saliva, urine, amniotic fluid, ?)
Details of biobank content	Serum bank, lymph bank, cell bank.
Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services
Care consumption (detail)	Medicines consumption
Procedures	
Data collection method	Self-administered questionnaire: entry from a paper questionnaire; Interviews: entry from a paper questionnaire; Clinical examinations: handwritten Biological analysis: handwritten
Quality procedure(s) used	Consistency request after electronic data is recorded. Missing data is managed by returning to source record. Physician reminder for follow-up visits. Patients are informed about the use of their data.
Participant monitoring	Yes
Details on monitoring of participants	Every 6 months.

Links to administrative sources	Yes
---------------------------------	-----

Linked administrative sources (detail)	CépiDc, RNIPP, InVS
--	---------------------

Promotion and access

Promotion

Link to the document	http://tinyurl.com/HAL-ANRS-CO2
----------------------	---

Description	List of publications in HAL
-------------	-----------------------------

Link to the document	http://tinyurl.com/Pubmed-ANRS-CO2
----------------------	---

Description	List of publications in Pubmed
-------------	--------------------------------

Access

Terms of data access (charter for data provision, format of data, availability delay)	Data may be used by academic teams. Data may not be used by industrial teams.
---	--

Access to aggregated data	Access on specific project only
---------------------------	---------------------------------

Access to individual data	Access on specific project only
---------------------------	---------------------------------